JEFFREY E GERSHENWALD to Antineoplastic Agents, Immunological
This is a "connection" page, showing publications JEFFREY E GERSHENWALD has written about Antineoplastic Agents, Immunological.
Connection Strength
0.185
-
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.
Score: 0.088
-
Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
Score: 0.077
-
Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018 08 01; 29(8):1861-1868.
Score: 0.020